|
covid-19 |
33 |
|
sars-cov-2 |
29 |
|
coronavirus |
28 |
|
burkholderia pseudomallei |
17 |
|
melioidosis |
17 |
|
adult |
16 |
|
biomarkers |
16 |
|
diagnosis |
16 |
|
metabolomics |
16 |
|
animal |
14 |
|
anosmia |
14 |
|
olfactory dysfunction |
14 |
|
acute hepatitis |
12 |
|
bronchiectasis |
12 |
|
case report |
12 |
|
chronic obstructive lung disease |
12 |
|
hepatitis e |
12 |
|
transmission |
12 |
|
epidemiology |
11 |
|
hamster |
11 |
|
mouse |
11 |
|
murine |
11 |
|
n501y |
11 |
|
rat |
11 |
|
sars-cov-2 variants |
11 |
|
susceptibility |
11 |
|
airborne infection |
10 |
|
hepatitis |
10 |
|
plasma |
10 |
|
zoonosis |
10 |
|
aged |
9 |
|
bioaerosols |
9 |
|
operating rooms |
9 |
|
pandemic |
9 |
|
resting-state fmri |
9 |
|
smell impairment |
9 |
|
temperature |
9 |
|
vitamin a |
9 |
|
aerosolised |
8 |
|
asymptomatic |
8 |
|
conjunctiva |
8 |
|
diagnostic test evaluation |
8 |
|
functional brain network |
8 |
|
long covid |
8 |
|
mask |
8 |
|
olfactory training |
8 |
|
real-time rt-pcr |
8 |
|
recombination |
8 |
|
rt-pcr |
8 |
|
shedding |
8 |
|
smell loss |
8 |
|
vaccine |
8 |
|
autoclave |
7 |
|
clade |
7 |
|
clinic |
7 |
|
cytomegalovirus |
7 |
|
dental |
7 |
|
diagnostic |
7 |
|
diagnostics |
7 |
|
enterovirus d68 |
7 |
|
evaluation |
7 |
|
flavivirus |
7 |
|
high infection rate |
7 |
|
human herpesvirus 6b |
7 |
|
infectivity |
7 |
|
lightmix e-gene |
7 |
|
middle east respiratory syndrome |
7 |
|
olfactory neuron |
7 |
|
pathogenesis |
7 |
|
pneumonia |
7 |
|
polymerase chain reaction |
7 |
|
route of transmission |
7 |
|
saliva |
7 |
|
screening |
7 |
|
single-tube nested |
7 |
|
stability |
7 |
|
sterilization |
7 |
|
untranslated |
7 |
|
virus |
7 |
|
zika |
7 |
|
antibody assay |
6 |
|
brain |
6 |
|
community |
6 |
|
coxsackievirus a6 |
6 |
|
face mask |
6 |
|
flow cytometry |
6 |
|
genotyping |
6 |
|
hand-foot-and-mouth disease |
6 |
|
health care workers |
6 |
|
hepatitis c virus |
6 |
|
hev-c1 |
6 |
|
hong kong |
6 |
|
human adenovirus |
6 |
|
laboratory |
6 |
|
liver disease |
6 |
|
newly-weaned hamster |
6 |
|
novel |
6 |
|
outbreak |
6 |
|
pooling |
6 |
|
public health |
6 |
|
rat hepatitis e |
6 |
|
real-time pcr |
6 |
|
realstar® adenovirus pcr kit |
6 |
|
rodent |
6 |
|
serology |
6 |
|
specific |
6 |
|
viral hepatitis |
6 |
|
abbott real time hcv genotype ii |
5 |
|
air sampling |
5 |
|
alere i flu a & b |
5 |
|
antibiotic therapy |
5 |
|
antimicrobial activity |
5 |
|
bacterial gene |
5 |
|
bactrian camel |
5 |
|
contact examination |
5 |
|
controlled study |
5 |
|
disseminated infection recurrence rate |
5 |
|
epidemic |
5 |
|
hepatitis c |
5 |
|
herpes simplex virus 2 |
5 |
|
herpesviridae |
5 |
|
human alphaherpesvirus 1 |
5 |
|
influenza virus |
5 |
|
mers |
5 |
|
middle east |
5 |
|
multiplex real time polymerase chain reaction |
5 |
|
mycobacterium avium complex |
5 |
|
non-hiv immunosuppression |
5 |
|
primary prophylaxis |
5 |
|
rapid molecular test |
5 |
|
recombinant |
5 |
|
secondary prophylaxis |
5 |
|
seroepidemiological study |
5 |
|
smell training |
5 |
|
xpert xpress flu/rsv |
5 |
|
accident & emergency medicine |
4 |
|
bacteremia |
4 |
|
blood sampling |
4 |
|
capping phenomenon |
4 |
|
carbapenemase-producing enterobacteriaceae |
4 |
|
chronic infection |
4 |
|
clinical laboratory |
4 |
|
cross-species transmission |
4 |
|
disease surveillance |
4 |
|
disinfection |
4 |
|
dromedary camel |
4 |
|
endemicity |
4 |
|
feasibility studies |
4 |
|
gastrointestinal colonization |
4 |
|
genotype 6 |
4 |
|
genotypes |
4 |
|
hepatitis e virus |
4 |
|
human hepegivirus 1 |
4 |
|
human herpesvirus 6 |
4 |
|
infectious diseases |
4 |
|
molecular epidemiology |
4 |
|
molecular evolution |
4 |
|
prolonged neutropenia |
4 |
|
qualitative research |
4 |
|
randomized controlled trial |
4 |
|
realstar® hhv-6 pcr kit |
4 |
|
swine |
4 |
|
taxonomy |
4 |
|
zoonotic infections |
4 |
|
anti-aquaporin-4 antibody |
3 |
|
autoimmune disorders |
3 |
|
autoimmune hepatitis |
3 |
|
civilian populations |
3 |
|
coinfection |
3 |
|
directly observed |
3 |
|
environmental hygiene |
3 |
|
evolution |
3 |
|
fatal infection |
3 |
|
genome recombination |
3 |
|
hand hygiene |
3 |
|
hiv |
3 |
|
host adaptation |
3 |
|
human |
3 |
|
human adenovirus type 4 |
3 |
|
immunization |
3 |
|
immunocompromised patient |
3 |
|
immunoglobulin |
3 |
|
inflammatory eye disease |
3 |
|
matrix-assisted laser desorption–ionization time-of-flight mass spectrometer |
3 |
|
neuromyelitis optica |
3 |
|
ophthalmic considerations |
3 |
|
parainfluenza |
3 |
|
plantar warts |
3 |
|
rhinovirus |
3 |
|
sexually transmitted diseases |
3 |
|
staff education |
3 |
|
surveillance |
3 |
|
talaromyces marneffei |
3 |
|
traditional chinese medicine |
3 |
|
transplantation |
3 |
|
tuberculosis |
3 |
|
viral |
3 |
|
zijinding |
3 |
|
animal model |
2 |
|
antiviral therapy |
2 |
|
babao dan |
2 |
|
cytomegalic endothelial cell |
2 |
|
etiology |
2 |
|
health-seeking behavior |
2 |
|
hepatitis epregnancy |
2 |
|
persons who inject drugs |
2 |
|
pleural empyema |
2 |
|
pregnancy outcome |
2 |
|
prevalence |
2 |
|
rhinosinusitis |
2 |
|
ribavirin |
2 |
|
seroepidemiology |
2 |
